tetano
Editor, Senior Moderator
J Gastroenterol
. 2022 Jan 28.
doi: 10.1007/s00535-022-01851-1. Online ahead of print.
Interim analysis of a multicenter registry study of COVID-19 patients with inflammatory bowel disease in Japan (J-COSMOS)
Hiroshi Nakase[SUP] 1 [/SUP], Yuki Hayashi[SUP] 2 [/SUP], Daisuke Hirayama[SUP] 2 [/SUP], Takayuki Matsumoto[SUP] 3 [/SUP], Minoru Matsuura[SUP] 4 [/SUP], Hideki Iijima[SUP] 5 [/SUP], Katsuyoshi Matsuoka[SUP] 6 [/SUP], Naoki Ohmiya[SUP] 7 [/SUP], Shunji Ishihara[SUP] 8 [/SUP], Fumihito Hirai[SUP] 9 [/SUP], Daiki Abukawa[SUP] 10 [/SUP], Tadakazu Hisamatsu[SUP] 4 [/SUP], J-COSMOS group
Collaborators, Affiliations
Abstract
Background: The spread of coronavirus disease 2019 (COVID-19) had a major impact on the health of people worldwide. The clinical background and clinical course of inflammatory bowel disease (IBD) among Japanese patients with COVID-19 remains unclear.
Methods: This study is an observational cohort of Japanese IBD patients diagnosed with COVID-19. Data on age, sex, IBD (classification, treatment, and activity), COVID-19 symptoms and severity, and treatment of COVID-19 were analyzed.
Results: From 72 participating facilities in Japan, 187 patients were registered from June 2020 to October 2021. The estimated incidence of COVID19 in Japanese IBD patients was 0.61%. The majority of IBD patients with COVID-19 (73%) were in clinical remission. According to the WHO classification regarding COVID-19 severity, 93% (172/184) of IBD patients had non-severe episodes, while 7% (12/184) were severe cases including serious conditions. 90.9% (165/187) of IBD patients with COVID-19 had no change in IBD disease activity. A logistic regression analysis stepwise method revealed that older age, higher body mass index (BMI), and steroid use were independent risk factors for COVID-19 severity. Six of nine patients who had COVID-19 after vaccination were receiving anti-tumor necrosis factor (TNF)-α antibodies.
Conclusion: Age, BMI and steroid use were associated with COVID-19 severity in Japanese IBD patients.
Keywords: Anti-TNF-α antibodies; COVID-19; Inflammatory bowel disease; SARS-CoV-2; Steroid.
. 2022 Jan 28.
doi: 10.1007/s00535-022-01851-1. Online ahead of print.
Interim analysis of a multicenter registry study of COVID-19 patients with inflammatory bowel disease in Japan (J-COSMOS)
Hiroshi Nakase[SUP] 1 [/SUP], Yuki Hayashi[SUP] 2 [/SUP], Daisuke Hirayama[SUP] 2 [/SUP], Takayuki Matsumoto[SUP] 3 [/SUP], Minoru Matsuura[SUP] 4 [/SUP], Hideki Iijima[SUP] 5 [/SUP], Katsuyoshi Matsuoka[SUP] 6 [/SUP], Naoki Ohmiya[SUP] 7 [/SUP], Shunji Ishihara[SUP] 8 [/SUP], Fumihito Hirai[SUP] 9 [/SUP], Daiki Abukawa[SUP] 10 [/SUP], Tadakazu Hisamatsu[SUP] 4 [/SUP], J-COSMOS group
Collaborators, Affiliations
- PMID: 35089397
- DOI: 10.1007/s00535-022-01851-1
Abstract
Background: The spread of coronavirus disease 2019 (COVID-19) had a major impact on the health of people worldwide. The clinical background and clinical course of inflammatory bowel disease (IBD) among Japanese patients with COVID-19 remains unclear.
Methods: This study is an observational cohort of Japanese IBD patients diagnosed with COVID-19. Data on age, sex, IBD (classification, treatment, and activity), COVID-19 symptoms and severity, and treatment of COVID-19 were analyzed.
Results: From 72 participating facilities in Japan, 187 patients were registered from June 2020 to October 2021. The estimated incidence of COVID19 in Japanese IBD patients was 0.61%. The majority of IBD patients with COVID-19 (73%) were in clinical remission. According to the WHO classification regarding COVID-19 severity, 93% (172/184) of IBD patients had non-severe episodes, while 7% (12/184) were severe cases including serious conditions. 90.9% (165/187) of IBD patients with COVID-19 had no change in IBD disease activity. A logistic regression analysis stepwise method revealed that older age, higher body mass index (BMI), and steroid use were independent risk factors for COVID-19 severity. Six of nine patients who had COVID-19 after vaccination were receiving anti-tumor necrosis factor (TNF)-α antibodies.
Conclusion: Age, BMI and steroid use were associated with COVID-19 severity in Japanese IBD patients.
Keywords: Anti-TNF-α antibodies; COVID-19; Inflammatory bowel disease; SARS-CoV-2; Steroid.